L3VLUP
ProSign in

GMED in the 13F filings

Globus Medical Inc · CUSIP 379577208

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Jun 2024
the date the book describes
Filed
14 Aug 2024
latest of these filings; the earliest 25 Jul 2024
Managers listing it
13
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q1 2024 and Q2 2024; 8 listed it in both
Shares listed
15,258,410
combined, among listed positions
Reported value
$1.0bn
combined, at the quarter end

Among the 94 comparable managers: 6 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing GMED in Q2 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

13 of 13 holders

ActionFiling
Janus Henderson Group Ltd7,384,889$506m0.27%Trimmed-277,50614 Aug 2024 (the filing on sec.gov)
Wellington Management Group LLP3,209,729$220munder 0.1%Trimmed-40,07914 Aug 2024 (the filing on sec.gov)
Millennium Management LLC1,363,834$93munder 0.1%Addedn.a.14 Aug 2024 (the filing on sec.gov)
Marshall Wace LLP957,734$66m0.09%Trimmed-271,70614 Aug 2024 (the filing on sec.gov)
Capital World Investors574,500$39munder 0.1%Held013 Aug 2024 (the filing on sec.gov)
Two Sigma Advisers LP529,875$36m0.08%Trimmed-201,10014 Aug 2024 (the filing on sec.gov)
Two Sigma Investments LP373,310$26m0.06%Trimmed-340,00514 Aug 2024 (the filing on sec.gov)
ExodusPoint Capital Management LP365,034$25m0.17%Newnew13 Aug 2024 (the filing on sec.gov)
Woodline Partners LP138,528$9.5m0.09%Newnew14 Aug 2024 (the filing on sec.gov)
GAMCO Investors Inc136,931$9.4m0.10%Trimmed-2,38913 Aug 2024 (the filing on sec.gov)
Bridgewater Associates LP129,362$8.9munder 0.1%Addedn.a.14 Aug 2024 (the filing on sec.gov)
Baillie Gifford & Co91,084$6.2munder 0.1%Added+1825 Jul 2024 (the filing on sec.gov)
Farallon Capital Management LLC3,600$247kunder 0.1%Newnew14 Aug 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2024 to Q2 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (3)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
12 in Q3 2024 to 10 in Q2 2026

Tracked managers listing it, at least.

01020302014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GMED by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20132$32mn.a.n.a.
Q3 20132$131mn.a.n.a.
Q4 20132$154mn.a.n.a.
Q1 20142$188mn.a.n.a.
Q2 20146$144mn.a.n.a.
Q3 20144$134mn.a.n.a.
Q4 20144$136mn.a.n.a.
Q1 20153$154mn.a.n.a.
Q2 20154$195mn.a.n.a.
Q3 20155$155mn.a.n.a.
Q4 20152$215mn.a.n.a.
Q1 20164$194mn.a.n.a.
Q2 20163$200mn.a.n.a.
Q3 20163$215mn.a.n.a.
Q4 20164$232mn.a.n.a.
Q1 20174$233mn.a.n.a.
Q2 20172$266mn.a.n.a.
Q3 20175$341mn.a.n.a.
Q4 20175$482mn.a.n.a.
Q1 20187$588mn.a.n.a.
Q2 20187$513mn.a.n.a.
Q3 201813$674mn.a.n.a.
Q4 201813$570mn.a.n.a.
Q1 20195$619mn.a.n.a.
Q2 20195$589mn.a.n.a.
Q3 20196$733mn.a.n.a.
Q4 201912$832mn.a.n.a.
Q1 20207$597mn.a.n.a.
Q2 20206$610mn.a.n.a.
Q3 20208$639mn.a.n.a.
Q4 20206$855mn.a.n.a.
Q1 20217$779mn.a.n.a.
Q2 202110$997mn.a.n.a.
Q3 20219$871mn.a.n.a.
Q4 202110$912mn.a.n.a.
Q1 202210$934mn.a.n.a.
Q2 20227$684mn.a.n.a.
Q3 20226$781mn.a.n.a.
Q4 20226$840mn.a.n.a.
Q1 202315$720mn.a.n.a.
Q2 202321$946mn.a.n.a.
Q3 202317$881mn.a.n.a.
Q4 202312$912m57
Q1 20248$772m25
Q2 202413$1.0bn66
Q3 202412$868m56
Q4 202414$1.4bn56
Q1 202513$951m94
Q2 202512$897m101
Q3 202511$765m64
Q4 202513$1.6bn1220
Q1 202614$1.6bn1915
Q2 202610$1.1bn1418

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GMED and LLY →GMED and JNJ →GMED and VRTX →Choose a stock to compare with GMED →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GMED, latest filings →Back to the 13F Explorer →